Serum and blood based biomarkers for lung cancer screening: a systematic review
Open Access
- 13 February 2018
- journal article
- review article
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-6
Abstract
Lung cancer is the second most common cancer and the leading cause of cancer death for both men and women. Although low-dose CT (LDCT) is recommended for lung cancer screening in high-risk populations and may decrease lung cancer mortality, there is a need to improve the accuracy of lung cancer screening to decrease over-diagnosis and morbidity. Blood and serum-based biomarkers, including EarlyCDT-lung and microRNA based biomarkers, are promising adjuncts to LDCT in lung cancer screening. We evaluated the diagnostic performance of EarlyCDT-lung, micro-RNA signature classifier (MSC), and miR-test, and their impact on lung cancer-related mortality and all-cause mortality. References were identified using searches of PubMed, EMBASE, and Ovid Medline® from January 2000 to November 2015. Phase three or greater studies in the English language evaluating the diagnostic performance of EarlyCDT-lung, MSC, and miR-test were selected for inclusion. Three phase 3 studies were identified, one evaluating EarlyCDT-lung, one evaluating miR-Test, and one evaluating MSC respectively. No phase 4 or 5 studies were identified. All three biomarker assays show promise for the detection of lung cancer. MSC shows promise when used in conjunction with LDCT for lung cancer detection, achieving a positive likelihood ratio of 18.6 if both LDCT and MSC are positive, and a negative likelihood ratio of 0.03 if both LDCT and MSC are negative. However, there is a paucity of high-quality studies that can guide clinical implementation. There is currently no high quality evidence to support or guide the implementation of these biomarkers in clinical practice. Reports of further research at stages four and five for these, and other promising methods, is required.Keywords
This publication has 20 references indexed in Scilit:
- Cancer incidence and mortality projections in the UK until 2035British Journal of Cancer, 2016
- Screening for lung cancer: A systematic review and meta-analysisPreventive Medicine, 2016
- Current and future molecular diagnostics in non-small-cell lung cancerExpert Review of Molecular Diagnostics, 2015
- miR-Test: A Blood Test for Lung Cancer Early DetectionJNCI: Journal of the National Cancer Institute, 2015
- Lung Cancer Screening Beyond Low-Dose Computed Tomography: The Role of Novel BiomarkersLung, 2014
- Updates and Controversies in the Rapidly Evolving Field of Lung Cancer Screening, Early Detection, and ChemopreventionCancers, 2014
- Clinical Utility of a Plasma-Based miRNA Signature Classifier Within Computed Tomography Lung Cancer Screening: A Correlative MILD Trial StudyJournal of Clinical Oncology, 2014
- Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: An evaluation of its performance in routine clinical practiceLung Cancer, 2014
- Lung Cancer Epigenetics: Emerging BiomarkersBiomarkers in Medicine, 2013
- Annual or biennial CT screening versus observation in heavy smokersEuropean Journal Of Cancer Prevention, 2012